慢性阻塞性肺疾病患者铜绿假单胞菌感染的临床分析及治疗

发布时间：2018-08-03 11:42

【摘要】：目的探讨慢性阻塞性肺疾病患者痰培养铜绿假单胞菌感染耐药性,以便早期预防与控制,为临床资料提供参考依据。方法选取2010年4月-2013年4月79例慢性阻塞性肺疾病患者送检痰培养分离出的铜绿假单胞菌进行耐药性分析,药敏试验采用琼脂扩散法和琼脂稀释法进行。结果慢性阻塞性肺疾病患者痰培养共分离出铜绿假单胞菌115株,对其耐药性较高的有亚胺培南和美罗培南,分别为13.91%和14.78%,而敏感性较高的是头孢他啶和阿米卡星,耐药率分别为6.09%和7.83%;亚胺培南和美罗培南对不同年份分离铜绿假单胞菌MIC值,亚胺培南均较美罗培南高,两者比较差异有统计学意义(P0.05),但是同种药物在不同年份比较则差异无统计学意义;MIC分布亚胺培南MIC≤1μg/ml占31.37%,2~4μg/ml占68.63%,而美罗培南MIC≤1μg/ml占55.4%,2~4μg/ml占44.6%,两者比较差异有统计学意义(P0.05)。结论慢性阻塞性肺疾病患者痰培养铜绿假单胞菌感染率及耐药性高,而美罗培南的耐药性较亚胺培南低。
[Abstract]:Objective to investigate the drug resistance of Pseudomonas aeruginosa infection in sputum culture in patients with chronic obstructive pulmonary disease (COPD) so as to prevent and control it early and provide reference for clinical data. Methods the drug resistance of Pseudomonas aeruginosa isolated from sputum culture of 79 patients with chronic obstructive pulmonary disease from April 2010 to April 2013 was analyzed. The drug sensitivity test was performed by Agar diffusion method and Agar dilution method. Results 115 strains of Pseudomonas aeruginosa were isolated in sputum culture from patients with chronic obstructive pulmonary disease. The resistant rates of imipenem and meropenem were 13.91% and 14.78%, respectively, while the sensitivity of ceftazidime and amikacin were higher. The drug resistance rates of imipenem and meropenem were 6.09% and 7.83%, respectively. The MIC values of imipenem and meropenem against Pseudomonas aeruginosa isolated in different years were higher than those of meropenem. There was significant difference between the two groups (P0.05), but there was no significant difference in the distribution of imipenem MIC 鈮，

本文编号：2161636